News Breaks |
|
|
| January 25, 2013 |
| 13:18 EDT |  | NVS | FDA approves Gleevec for children with acute lymphoblastic leukemia
The U.S. Food and Drug Administration approved a new use of Gleevec to treat children newly diagnosed with Philadelphia chromosome positive acute lymphoblastic leukemia. Gleevec’s safety and effectiveness for this new indication were established in a clinical trial conducted by the Children’s Oncology Group, sponsored by the National Cancer Institute. Fifty of the Ph+ ALL patients received Gleevec for the longest duration, and 70% of these patients did not experience relapse or death within four years. Results also showed patient deaths decreased with increasing duration of Gleevec treatment in combination with chemotherapy. Gleevec is marketed by Novartis (NVS). Reference Link |
|
|
News For NVS From The Last 14 Days Check below for free stories on NVS the last two weeks. |
|
|
| May 20, 2013 |
| 07:29 EDT |  | NVS | Deutsche Bank to host a conference
dbAccess Asia Conference 2013 is being held in Singapore on May 20-22. |
|
| May 17, 2013 |
| 16:20 EDT | | NVS | Novartis drug Afinitor extended time without disease progression in women
 Subscribe for More Information |
|
| May 16, 2013 |
| 08:11 EDT | | NVS | Novartis says no intention of pursuing Actavis, Bloomberg reports
Subscribe for More Information |
|
| May 15, 2013 |
| 19:37 EDT |  | NVS | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information |
|
| 18:17 EDT | | NVS | Novartis weighs possible bid for Actavis, DJ reports
Subscribe for More Information |
|
| May 10, 2013 |
| 05:42 EDT | | NVS | Novartis drug Ilaris approved by FDA
Subscribe for More Information |
|
|
|
|
|
